Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

4.200 +0.030 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 461,547
Open 4.120
Bid (Size) 4.080 (8)
Ask (Size) 4.500 (1)
Prev. Close 4.170
Today's Range 4.190 - 4.260
52wk Range 2.250 - 15.00
Shares Outstanding 61,758,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Via Benzinga
The Latest Analyst Ratings for Fulcrum Therapeutics
Via Benzinga

Performance

YTD
-46.84%
-46.84%
1 Month
-27.34%
-27.34%
3 Month
+35.48%
+35.48%
6 Month
+34.62%
+34.62%
1 Year
-47.37%
-47.37%

More News

Read More
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FULC Long Term Investor Alert: Investigation of Potential Wrongdoing at Fulcrum Therapeutics, Inc.
Via SBWire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
Via FinancialNewsMedia
Exposures Product Safety
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Why Splunk Are Trading Higher By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Dollar Tree, Burlington Stores, Opera And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Fulcrum Therapeutics To Rally Around 120%? FDA Update Removes Overhang On Pivotal Program
Via Benzinga
Exposures Product Safety
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Via Benzinga
Dow Falls Over 100 Points; US Existing Home Sales Decline In July
Via Benzinga
Topics Stocks
Exposures US Equities
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Exposures Product Safety
Fulcrum Therapeutics Inc. (NASDAQ: FULC) Near Top of Volume Charts in Tuesday Trading
Via Investor Brand Network
Why Is Fulcrum Therapeutics Stock Surging Today?
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
Via Benzinga
Fulcrum Therapeutics, AMTD Digital, Hasbro And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
BLNK Stock Alert: Blink Charging Signs Deal to Bring EV Charging to McDonald’s
Via InvestorPlace
US Stocks Mixed; Lowe's Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
APP Stock Price Predictions: Is AppLovin Really Worth $50?
Via InvestorPlace
Why Is Fulcrum Therapeutics (FULC) Stock Up 43% Today?
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.